Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Rossari Biotech's Debt-to-EBITDA or its related term are showing as below:
NSE:ROSSARI'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.04 Med: 0.47 Max: 1.41
Current: 1.34
During the past 9 years, the highest Debt-to-EBITDA Ratio of Rossari Biotech was 1.41. The lowest was 0.04. And the median was 0.47.
NSE:ROSSARI's Debt-to-EBITDA is ranked better than 63.09% of 1238
companies
in the Chemicals industry
Industry Median: 2.15
vs NSE:ROSSARI: 1.34
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Rossari Biotech Debt-to-EBITDA Related Terms
Rossari Biotech Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Rossari Biotech's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ROSSARI vs LIN, SHW, ECL: Debt-to-EBITDA Comparison
For the Specialty Chemicals subindustry, Rossari Biotech's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rossari Biotech Debt-to-EBITDA vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Rossari Biotech's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Rossari Biotech's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Rossari Biotech (NSE:ROSSARI) has a Debt-to-EBITDA of 0.00 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Rossari Biotech. Over the past decade, Rossari Biotech's Debt-to-EBITDA has ranged from 0.04 to 1.41. According to the industry distribution chart, Rossari Biotech ranks #457 out of 1238 companies in the Chemicals industry, placing it in the top 36.9%.
Is Rossari Biotech's Debt-to-EBITDA too high?
Rossari Biotech's current Debt-to-EBITDA is 0.00. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 1.41. Based on the distribution chart, Rossari Biotech ranks #457 out of 1238 companies in the Chemicals industry, which is above the industry midpoint. Overall, Rossari Biotech has a GF Score™ of 84/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Rossari Biotech's Debt-to-EBITDA compare to LIN and SHW?
According to the Chemicals industry distribution chart, Rossari Biotech ranks #457 out of 1238 companies for Debt-to-EBITDA. This puts Rossari Biotech in the upper half of its industry. The industry median Debt-to-EBITDA is 2.15. Historically, Rossari Biotech's own Debt-to-EBITDA has ranged from 0.04 to 1.41 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Chemicals company?
The median Debt-to-EBITDA among Chemicals companies is 2.15, based on 1,238 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Rossari Biotech. For the Chemicals industry, the median Debt-to-EBITDA is 2.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rossari Biotech's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rossari Biotech stock overvalued right now?
Based on GuruFocus' analysis, Rossari Biotech (NSE:ROSSARI) is currently considered Possible Value Trap. The stock's GF Value™ is ₹951.67, compared to a current price of ₹513.95 — trading 46% below its estimated fair value. The current Debt-to-EBITDA is 0.00. Rossari Biotech's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Rossari Biotech (NSE:ROSSARI), the current Debt-to-EBITDA is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rossari Biotech (NSE:ROSSARI) Overvalued in 2026?
Based on GuruFocus' analysis, Rossari Biotech stock appears to be undervalued.
The current stock price of ₹513.95 is trading 46% below its estimated GF Value™ of ₹951.67.
GuruFocus considers Rossari Biotech to be Possible Value Trap.
Key valuation signals for NSE:ROSSARI:
Debt-to-EBITDA: 0.00
GF Value™: ₹951.67 vs. price of ₹513.95 (46% below fair value)
No single metric tells the full story. See the NSE:ROSSARI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rossari Biotech Ltd is a specialty chemical manufacturing company. It provides customized solutions to specific industrial and production requirements of its customers in the FMCG, apparel, poultry, and animal feed industries through its product portfolio comprising home, personal care, and performance chemicals; textile specialty chemicals; and animal health and nutrition products. Its business is organized into three categories: home, personal care, and performance chemicals; textile specialty chemicals; and animal health and nutrition products. Its products include soaps and detergents, paints, inks and coatings, ceramics and tiles, water treatment chemicals, pulp and paper, and cleaning chemical formulations, among others. The company generates the majority revenue from India.
84GF Score
Get the complete analysis for NSE:ROSSARI
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ROSSARI has been successfully added to your 
